Related by context. All words. (Click for frequent words.) 83 placebo controlled studies 76 placebo controlled clinical trials 76 randomized clinical trials 75 randomized controlled trials 75 randomized trials 75 randomized controlled clinical trials 72 RCTs 69 subgroup analyzes 69 active comparator 68 fluvastatin 68 placebo controlled 68 HCV SPRINT 68 meta analyzes 68 placebo controlled clinical 68 nonrandomized 68 reboxetine 67 observational studies 67 randomized controlled 67 trials RCTs 66 RRMS patients 66 DAPT 66 randomized controlled trials RCTs 66 cilostazol 66 ARCOXIA 66 divalproex sodium 65 randomized placebo controlled 65 dose regimens 65 teriflunomide 65 MERLIN TIMI 65 riociguat 65 antiepileptics 65 multicenter randomized 65 RE LY 65 fluoxetine Prozac 65 NATRECOR ® 65 adalimumab 65 randomized clinical 65 citalopram 65 HCV RESPOND 2 64 multicenter trials 64 placebo controlled randomized 64 placebo controlled Phase 64 dosing cohorts 64 abatacept 64 dosage regimens 64 lacosamide 64 RLAI 64 APTIVUS r 64 randomized controlled trial 64 PREZISTA r 64 phase IIIb 64 levetiracetam 64 glatiramer acetate 64 ONGLYZA 64 NATRECOR R 64 CANCIDAS 64 randomized multicenter 64 montelukast 64 ADAGIO study 64 ATACAND 64 ziprasidone 64 solifenacin 64 double blinded randomized 64 epidemiologic studies 64 randomized multicenter trial 64 placebo controlled Phase III 64 Focalin XR 64 dabigatran etexilate 63 prucalopride 63 noninferiority 63 Betaferon ® 63 rosuvastatin 63 oral rivaroxaban 63 paroxetine Paxil 63 tocilizumab 63 lipid lowering therapy 63 neuropsychiatric symptoms 63 mg doses 63 temsirolimus 63 bendamustine 63 Subgroup analyzes 63 Ophena TM 63 oral diclofenac 63 HORIZONS AMI trial 63 inhaled anticholinergics 63 multicenter placebo controlled 63 CYPHER R Sirolimus eluting 63 Celebrex celecoxib 63 ARIXTRA 63 Traficet EN 63 pharmacokinetic studies 63 blinded placebo controlled 63 salmeterol fluticasone 63 RSD# oral 63 rFVIIa 63 lipid lowering agents 63 β blockers 63 CAMMS# 63 Mylotarg 63 meta analysis 63 randomized controlled clinical 63 venlafaxine 63 antiplatelet drugs 63 MIRAPEX 63 tiotropium 63 FROVA 63 EURIDIS 62 thromboprophylaxis 62 mycophenolate mofetil 62 RoACTEMRA 62 atorvastatin Lipitor 62 TYGACIL 62 venlafaxine XR 62 RE LY ® 62 venlafaxine Effexor 62 phase IIa 62 SEROQUEL XR 62 dosing regimens 62 randomized multicenter Phase III 62 substudy 62 NOXAFIL 62 topical NSAIDs 62 risperidone Risperdal 62 GnRH agonists 62 prospective observational 62 pramipexole 62 canakinumab 62 NMDA receptor antagonists 62 multicenter randomized placebo controlled 62 bicifadine 62 AVERROES 62 desvenlafaxine succinate 62 multicentre 62 antihypertensive drugs 62 VADT 62 pharmacokinetic characteristics 62 sorafenib Nexavar 62 Pemetrexed 62 #mg dose [001] 62 flutamide 62 tapentadol ER 62 efalizumab 62 antiepileptic drug 62 sertraline Zoloft 62 Clinical Antipsychotic Trials 62 tibolone 62 clinical pharmacology studies 62 icatibant 62 GAMMAGARD 62 Intervention Effectiveness 62 secondary efficacy endpoints 62 vicriviroc 62 antimuscarinic 62 bosentan 62 relapsed MM 62 AZILECT R 62 multicenter study 62 mg dose 62 phase IIb 62 donepezil 62 Paxil paroxetine 62 ExTRACT TIMI 62 COPAXONE R 62 LATUDA 62 clomipramine 62 genotypic resistance 62 quetiapine 62 antiepileptic drugs AEDs 62 escitalopram 62 viral kinetic 62 TAXUS VI 62 dose titration 62 dosing intervals 62 antiepileptic drugs 62 dosing cohort 62 #mg dose [003] 62 calcineurin inhibitors 62 mirtazapine 62 iniparib 62 lasofoxifene 62 Intervention Effectiveness CATIE 62 #mg dose [002] 62 nab paclitaxel 62 ACTEMRA TM 62 VFEND 62 oxcarbazepine 61 GSK# [001] 61 prospectively defined 61 axitinib 61 MAGE A3 ASCI 61 #mg doses [002] 61 SPARCL 61 Torisel 61 telcagepant 61 eszopiclone 61 oral FTY# 61 INVEGA ® 61 zafirlukast 61 ACCORD Lipid 61 pomalidomide 61 prospective randomized 61 dose escalation Phase 61 PRISTIQ 61 multicenter multinational 61 goserelin 61 ALLHAT 61 ximelagatran 61 ramelteon 61 protease inhibitor PI 61 idraparinux 61 comparator arm 61 tigecycline 61 controlled multicenter 61 safinamide 61 phase IIb trial 61 CIMZIA TM certolizumab pegol 61 AIM HIGH 61 ORENCIA ® 61 observational study 61 androgen suppression 61 multicenter 61 mcg doses 61 TEAEs 61 efficacy 61 FOSRENOL R 61 sertraline 61 FOLPI 61 interferon gamma 1b 61 aripiprazole 61 clinical trials 61 antihypertensive therapy 61 risperidone olanzapine 61 tolvaptan 61 typical antipsychotics 61 retrospective observational study 61 ARIMIDEX 61 posaconazole 61 UKPDS 61 GOUT 61 Dacogen injection 61 analgesic efficacy 61 JANUVIA 61 interferon alfa 2b 61 perphenazine 61 Randomized trials 61 oral bisphosphonates 61 lanthanum carbonate 61 Topiramate 61 LY# [003] 61 mcg dose 61 DDP# 61 rt PA 61 bupropion SR 61 LEXIVA r 61 tiagabine 61 pioglitazone Actos 61 LEVAQUIN ® 61 pegylated interferon alfa 2b 61 low dose cytarabine 61 FOSRENOL ® 61 aripiprazole Abilify 61 arzoxifene 61 forodesine 61 AIR CF1 61 PRECiSE 61 peg IFN 61 milligram doses 61 serotonin norepinephrine reuptake inhibitor 61 Ranolazine 61 ascending dose 61 multicentre study 61 FASLODEX 61 BOLDER II 61 TORISEL 61 double blinded placebo 61 HAART regimens 61 pharmacokinetic interactions 61 valsartan 61 conventional antipsychotics 61 metastatic RCC 61 galantamine 61 bezafibrate 61 mg BID 61 tolterodine 61 KRAS status 60 cediranib 60 symptomatic BPH 60 Paroxetine 60 galiximab 60 oral ridaforolimus 60 CYPHER Stent 60 prospective randomized controlled 60 eprotirome 60 cabazitaxel 60 paclitaxel eluting stents 60 ASCEND HF 60 subanalysis 60 phase Ib 60 peginterferon 60 Phase IIIb study 60 newer antipsychotics 60 randomized Phase III 60 multicenter randomized double 60 blinded randomized placebo controlled 60 events SAEs 60 oral olanzapine 60 Xelox 60 APTIVUS 60 brivaracetam 60 Aptivus 60 PROMACTA 60 Levetiracetam 60 darunavir ritonavir 60 CYPHER ® Sirolimus eluting 60 AZILECT ® 60 tacrolimus ointment 60 retrospective cohort 60 anakinra 60 EDEMA3 60 candesartan 60 tricyclic antidepressants 60 Doxil ® 60 leukotriene receptor antagonists 60 prasugrel Effient 60 composite endpoint 60 5-FU/LV 60 ACZ# 60 eplerenone 60 Meta analyzes 60 QTc prolongation 60 zonisamide 60 dexmedetomidine 60 ACUITY trial 60 dose escalation 60 virologic response 60 teriparatide 60 Elitek 60 gadobutrol 60 citalopram Celexa 60 paliperidone ER 60 Afatinib 60 randomized blinded 60 cholinesterase inhibitor 60 valproate 60 etanercept 60 Keppra R 60 cardiac toxicity 60 strontium ranelate 60 pioglitazone 60 REMINYL ® 60 Quetiapine 60 testosterone supplementation 60 tamoxifen therapy 60 efavirenz EFV 60 GLYX 60 Raptiva ® 60 multicentre randomized 60 HPTN 60 multicenter Phase III 60 MoxDuo TM IR 60 aldosterone antagonists 60 standard chemotherapy regimen 60 chemoradiotherapy 60 Observational studies 60 XELOX 60 azacitidine 60 PRIMO CABG 60 APPRAISE 60 liver transplant recipients 60 EFFEXOR XR 60 Vimpat R 60 aldosterone antagonist 60 ORENCIA R 60 haloperidol Haldol 60 AIR2 Trial 60 amoxicillin clavulanate 60 treatment naive genotype 60 acting beta agonists 60 CIMZIA ™ 60 atypicals 60 paroxysmal AF 60 Pimavanserin 60 microgram doses 60 tenofovir DF 60 Tolvaptan 60 ConclusionThis 60 zolmitriptan 60 NEVO ™ 60 ginkgo extract 60 peginterferon alfa 2b 60 ritonavir boosted 60 fingolimod 60 heavily pretreated patients 60 pioglitazone HCl 60 rilonacept 60 NUVIGIL 60 Serious adverse reactions 60 prospective randomized multicenter 60 pramlintide metreleptin combination 60 double blind placebo 60 lamotrigine 60 recurrent VTE 60 pegylated interferon alfa 60 SEROQUEL 60 pregabalin 60 warfarin therapy 60 blind placebo 60 diuretic chlorthalidone 60 Tarceva TM 60 SGAs 60 NPH insulin 60 AGILECT ® 60 adjunctive placebo 60 ancrod 60 PRADAXA 60 clinically meaningful differences 59 atypical antipsychotic medications 59 cinacalcet 59 Betaferon R 59 antidepressant efficacy 59 budesonide foam 59 LUX Lung 59 Intervention Trial GAIT 59 Tiotropium 59 AZILECT 59 febuxostat 59 ibandronate 59 abacavir lamivudine 59 Phase III trials 59 Phase 1b trial 59 rotigotine 59 Subgroup analysis 59 trabectedin 59 tolerability profile 59 telmisartan 59 TNF inhibitor 59 olanzapine LAI 59 Phase IIB 59 ZOLINZA 59 Protelos 59 MIRCERA 59 denufosol 59 rosuvastatin Crestor 59 mCRC patients 59 Cytoxan 59 achieved statistical significance 59 dose cohorts 59 anti leukemic 59 telaprevir dosing 59 DMARDS 59 deferiprone 59 mapatumumab 59 Prozac fluoxetine 59 phase IIb clinical 59 INC# 59 6R BH4 59 HIV HCV coinfected 59 olanzapine Zyprexa 59 MAS XR 59 antihypertensive medications 59 YONDELIS 59 DU #b 59 viral kinetics 59 Cochrane reviewers 59 intravenous bisphosphonates 59 lumiracoxib 59 clevidipine 59 KRN# 59 metformin HCl 59 MADIT II 59 phase IIb study 59 Prostate AdenoCarcinoma Treatment 59 iPrEx study 59 apremilast 59 latrepirdine 59 imipramine 59 anticonvulsants 59 acamprosate 59 sipuleucel T 59 neuroleptics 59 IMPROVE IT 59 maximally tolerated dose 59 OvaRex ® MAb 59 HMG CoA reductase inhibitors 59 methotrexate monotherapy 59 insulin detemir 59 rilpivirine 59 infantile colic 59 ropinirole 59 tipranavir 59 lopinavir ritonavir 59 uric acid lowering 59 virologic failure 59 hepatotoxicity 59 rivaroxaban 59 ticagrelor 59 Prozac Paxil Zoloft 59 ALT flares 59 neratinib 59 dose cohort 59 thromboembolic events 59 tolerability profiles 59 entecavir 59 oral anticoagulation 59 GFT# 59 symptomatic VTE 59 docetaxel Taxotere ® 59 confirmatory clinical 59 ONTARGET 59 elotuzumab 59 Phase IIIb 59 ACEIs 59 dapsone 59 trastuzumab Herceptin ® 59 RezularTM 59 infliximab Remicade 59 ANCHOR trial 59 Clonicel 59 Octreolin 59 evaluable subjects 59 paliperidone palmitate 59 clopidogrel Plavix 59 BoNTA 59 STRIDE PD 59 ZYVOX 59 phase III isavuconazole 59 FOLFOX 59 rasagiline 59 migraine prophylaxis 59 Phase 2b study 59 Proellex TM 59 Abilify aripiprazole 59 fostamatinib 59 ABC/3TC 59 methotrexate therapy 59 vasomotor symptoms 59 oral antidiabetes drugs 59 interferon alfa 59 Phase IIb trial 59 pegylated interferons 59 dacarbazine 59 anastrozole 59 olanzapine 59 alvimopan 59 clinical trial 59 eltrombopag 59 VaD 59 BARI 2D 59 PROSTVAC TM 59 TDF FTC 59 ruboxistaurin 59 timepoints 59 pegylated liposomal doxorubicin 59 conjugated equine estrogen 59 mg/m2 dose 59 Non inferiority 59 TYKERB 59 non selective NSAIDs 59 ROCKET AF 59 INCB# [003] 59 plus ribavirin 59 zoledronate 59 bipolar mania trials 59 intravenous dosing 59 calcium supplementation 59 efficacy endpoints 59 aspirin clopidogrel 59 superficial bladder cancer 59 CHAMPION PLATFORM 59 mg kg dose 59 antiandrogens 59 certolizumab 59 irbesartan 59 nesiritide 59 Ilaris 59 afatinib 59 corrected QT interval 59 antiplatelet agents 59 Starlix 59 boosted protease inhibitor 59 ziprasidone Geodon 59 Symbyax 59 blinded placebo 59 CAELYX 59 BRIM3 59 Bezielle 59 INVEGA 59 decitabine 59 FOLFIRI 59 dose regimen 59 tegaserod 59 timepoint 59 Cochrane Systematic Review 59 PRE SURGE 59 metaanalysis 59 Tekturna HCT 59 peginterferon alfa 2a 59 KAPIDEX 59 AZOR 59 Perforomist Inhalation Solution 59 allopurinol 59 desvenlafaxine 59 CLARITY study 59 atherothrombotic events 59 diabetic neuropathic pain 59 Pharmacokinetic parameters 59 ARB telmisartan 59 masked placebo controlled 59 pitavastatin 59 phase IIa clinical 59 QT prolongation 59 NSABP B 59 Wisconsin Sleep Cohort 59 pazopanib 59 Golimumab 59 donepezil rivastigmine 59 briakinumab 59 prospective observational studies 59 Temsirolimus 59 coxibs 59 refractory CLL 59 relapsed SCLC 58 INVEGA R 58 ginkgo biloba extract 58 PEGINTRON TM 58 CHAMPION PCI 58 blind randomized placebo 58 Amrubicin 58 Phase 2a trial 58 nortriptyline 58 PD LID 58 ENDEAVOR IV 58 pharmacokinetic parameters 58 Allovectin 7 ® 58 palonosetron 58 Phase III Clinical Trials 58 tamsulosin 58 adenotonsillectomy 58 SCIg 58 paricalcitol 58 paroxetine Seroxat 58 SNRI 58 complete remissions 58 FOLFOX4 58 atazanavir 58 guanfacine 58 sildenafil Viagra 58 triptan 58 anti arrhythmic drug 58 QLT# 58 bupropion XL 58 selegiline 58 atomoxetine 58 gout flares 58 Dose escalation 58 REYATAZ ritonavir 58 bevacizumab Avastin 58 long acting bronchodilator 58 glucose lowering 58 intravenous cyclophosphamide 58 anti androgen 58 BYETTA exenatide injection 58 XIENCE V PROMUS Stent 58 Zemplar Capsules 58 pravastatin therapy 58 eculizumab therapy 58 zileuton 58 fluoxetine 58 ritonavir boosted atazanavir 58 nadolol 58 landmark ATHENA 58 Angiox R 58 R roscovitine 58 Phase III placebo controlled 58 fondaparinux 58 fluoxetine paroxetine 58 Rosuvastatin 58 hemostatic efficacy 58 bexarotene 58 doxazosin 58 DPNP 58 selenium supplementation 58 Phase IIa trial 58 randomized multicentre 58 Jevtana 58 beta blocker therapy 58 candesartan cilexetil 58 injectable formulations 58 bicalutamide 58 BENICAR HCT 58 ToGA 58 doxorubicin docetaxel 58 piroxicam 58 Avandia Actos 58 postmarketing surveillance 58 EMBEDA ™ 58 chlorthalidone 58 Onrigin 58 newer antipsychotic medications 58 metastatic HRPC 58 CLBP 58 ALGRX 58 quetiapine fumarate 58 stable angina 58 newer atypical antipsychotics 58 sunitinib malate 58 glargine 58 ISENTRESS 58 Instanyl 58 COPD exacerbations 58 evaluating mipomersen 58 chemotherapeutic regimens 58 sotalol 58 Femara letrozole 58 Diamyd ® 58 prospective randomized placebo 58 Arranon 58 milrinone 58 Bivalirudin 58 Neupro R 58 Trizivir 58 metformin sulfonylurea 58 Phase IIIb clinical 58 multicenter clinical 58 prospective multicenter 58 anticholinergics 58 Stenting Trial CREST 58 ketoconazole 58 B vitamin supplementation 58 intensive statin therapy 58 acitretin 58 venlafaxine ER 58 Phase III randomized 58 pyridostigmine 58 glitazones 58 AIR CF2 58 poor metabolizers 58 dexpramipexole 58 dacarbazine chemotherapy 58 primary hypercholesterolemia 58 non squamous NSCLC 58 Phase #/#a 58 randomized double 58 mg RDEA# 58 iPrEx 58 Randomized Phase 58 Cipralex ® 58 VIRAMUNE XR 58 Navelbine ® 58 Diabetic Macular Edema 58 colesevelam HCl 58 BARACLUDE ® 58 Dabigatran 58 prospective nonrandomized 58 pharmacodynamic properties 58 carcinogenicity studies 58 JAK Inhibitor 58 ß blockers 58 visilizumab 58 INTELENCE 58 cholinesterase inhibitors 58 Hycamtin 58 tolevamer 58 methodological limitations 58 pharmacologic treatments 58 lipid lowering medication 58 peginterferon alfa 58 valopicitabine 58 thorough QT 58 non inferiority 58 BRAF inhibitor 58 MabCampath 58 celecoxib 58 QTc 58 romiplostim 58 Vandetanib 58 ramipril 58 cladribine tablets 58 EQUIP OB 58 bronchial thermoplasty 58 RAPAFLO R 58 DMARD 58 alicaforsen enema 58 clinically meaningful improvements 58 dose escalation phase 58 pimecrolimus cream 58 monotherapy 58 antithrombotic therapy 58 definite stent thrombosis 58 epoetin alfa 58 antiandrogen 58 Detrol LA 58 selective serotonin reuptake inhibitor 58 Roche Xeloda 58 angiographic outcomes 58 TMC# C# 58 pharmacokinetic PK study 58 renal toxicity 58 dose limiting toxicities 58 postmarketing 58 elagolix 58 RISPERDAL ® 58 pharmacodynamics PD 58 baseline HbA1c 58 fenofibric acid 58 quetiapine Seroquel 58 trastuzumab DM1 58 OHR/AVR# 58 duloxetine Cymbalta 58 ACIPHEX 58 dyslipidaemia 58 CRESTOR #mg 58 lipid lowering 58 Fludara 58 dosing schedules 58 mitoxantrone 58 heavily pretreated 58 cannabinor 58 risperidone 58 Neurodex 58 nabilone 58 pharmacodynamic effects 58 insulin degludec 58 oral Hycamtin 58 certolizumab pegol 58 SAPHRIS 58 Engerix B 58 randomized Phase IIb 58 lipid lowering drugs 58 adipiplon 58 NO# [002] 58 IFN alfa 58 fosbretabulin 58 tesofensine 58 Plicera 58 alteplase 58 Peg IFN 58 darunavir 58 RE LY trial 58 unblinded 58 Lu AA# 58 Raptiva r 58 #mg/day [001] 58 blind randomized 58 topiramate Topamax 58 aclidinium 58 pimecrolimus 58 paliperidone 58 AVOREN 58 NNRTI resistance 58 valsartan Diovan 58 TRILIPIX 58 TRANSFORMS 58 MYCAMINE 58 lipid lowering medications 58 GSK# [002] 58 EDARBI 58 Ophena 58 analgesic medications 58 DLTs 58 antihypertensive agents 58 ACTEMRA 57 Teriflunomide 57 leflunomide 57 randomized 57 HZT 57 LPV r 57 prospective observational cohort 57 sunitinib 57 coadministration 57 albinterferon alfa 2b 57 maximal doses 57 inhaled budesonide 57 atypical antipsychotic 57 tipranavir r 57 olaparib 57 anti TNF 57 oral antidiabetic medication 57 peginterferon alpha 2a 57 endometrial hyperplasia 57 adenoma recurrence 57 Zolinza 57 cisplatin vinorelbine 57 AGILECT R 57 micafungin 57 Seliciclib 57 Hydroxyurea 57 MEVACOR 57 atrasentan 57 somatostatin analog 57 cerebral microbleeds 57 CCyR 57 ONGLYZA ™ 57 singleton pregnancies 57 tecarfarin 57 Fondaparinux 57 RESIST studies 57 AEGR 57 direct thrombin inhibitors 57 ribavirin therapy 57 Major Depressive Disorder 57 EmbraceAC 57 antiarrhythmic drug 57 aflibercept 57 dimebon 57 4CMenB 57 Prostate Cancer Prevention 57 efficacy tolerability 57 oral vancomycin 57 ZD# [001] 57 recurrent GBM 57 ziconotide 57 QT QTc 57 LIALDA 57 periprocedural MI 57 CLL8 57 Dapagliflozin 57 ECASS 57 sulfasalazine 57 DSMB 57 valacyclovir 57 NP2 Enkephalin 57 PTNS 57 Zoraxel 57 divalproex 57 COMFORT II 57 EDEMA4 57 Viread Emtriva 57 co trimoxazole 57 chronic angina 57 mg Proellex 57 amisulpride 57 NeuroStar TMS Therapy 57 Tocilizumab 57 nebulized formoterol fumarate 57 atypical antipsychotic drugs 57 dopamine partial agonist 57 rufinamide 57 coronary revascularization 57 Frova R 57 Dasatinib 57 mg BID dose 57 Safinamide 57 dalteparin 57 TOLAMBA 57 darapladib 57 Rebif ® 57 citalopram hydrobromide 57 amrubicin 57 mg Pycnogenol 57 CRLX# 57 R# #mg BID 57 antiepileptic medications 57 IBS C 57 mg administered orally 57 oral antidiabetic 57 ACTIVE W 57 CUSTOM III 57 Rivaroxaban 57 edoxaban 57 dose escalation clinical 57 longitudinal studies 57 trastuzumab emtansine T DM1 57 NNT = 57 blinded randomized controlled 57 HyQ 57 AVANDIA 57 melphalan prednisone 57 escitalopram Lexapro 57 nulliparous women 57 ABCSG 57 attain statistical significance 57 CYP#D# inhibitor 57 recurrent malignant glioma 57 spontaneous bowel movements 57 Microplasmin 57 carbidopa levodopa 57 prospective cohort 57 Sertraline 57 ketorolac 57 laquinimod 57 Adalimumab 57 Placebo Controlled Trial 57 MGd 57 perampanel 57 DEB# 57 Hepatotoxicity 57 docetaxel chemotherapy 57 octreotide LAR 57 torezolid phosphate 57 INVEGA ® SUSTENNA ® 57 multicenter randomized controlled 57 oral Xeloda 57 efficacy endpoint 57 Adlea 57 label dose titration 57 Genz # 57 AVELOX 57 nelfinavir